Latest Breaking News On - Pranav amin - Page 1 : comparemela.com

Alembic Pharma to launch 25 drugs in US generic segment in FY25

Alembic Pharma to launch 25 drugs in US generic segment in FY25
indiainfoline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiainfoline.com Daily Mail and Mail on Sunday newspapers.

Pranav aminAlembic pharmaceuticalAlembic pharma

Alembic Pharma Q2 Results: Firm posts Rs 137-crore net profit

Revenues grew 8% to Rs.1595 crore in Q2FY24 compared to Rs 1475 crore last year. The earnings before interest, tax, depreciation and amortization (EBITA) declined 6% YoY to Rs 218 crore. The EBITDA margins stood at 14% in Q2FY24.

Pranav aminNational list of essential medicineAlembic pharmaNational listEssential medicineAlembic pharma q2 resultsAlembic pharma q2Alembic pharma resultsAlembic pharma q2 earningsAlembic pharma shares

Youngest TiE chapter Vadodara announces mega event on Oct 20-21 themed Opportunities Unlimited

Youngest TiE chapter Vadodara announces mega event on Oct 20-21 themed Opportunities Unlimited
bilkulonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bilkulonline.com Daily Mail and Mail on Sunday newspapers.

Nilesh shuklaRafat quadriPranav aminVikram guptaPunit lalbhaiNyela kalsiaPadma shriRajeev chandrasekharPadmaja rupareliaArvind groupExposition centerTiecon vadodaraMinister rajeev chandrasekharMaking mouVenture capitalistsTie chapter

Alembic aims for US rebound with new launches

Alembic Pharmaceuticals plans to launch 20 new products in the US market in FY24, including oncology and non-oncology injectables, derma, and ophthalmic products. The launches will be facilitated by the newly USFDA-compliant facilities. The company also plans to take advantage of drug shortages in the US.

Pranav aminDrug administrationAlembic pharmaceuticalsIndian pharmaIndian company

neoplasm: Alembic Pharma posts Rs 121 crore net profit in Q1FY24

Alembic Pharma has reported a Q1 net profit of INR 121 crore, up from a net loss of INR 66 crore YoY, led by increased sales growth across its segments. The Indian branded business recorded a 9% YoY growth to INR 524 crore, while US generics saw 6% YoY growth to INR 354 crore.

Pranav aminAlembic pharmaAlembic pharma share priceAlembic pharma sharesMarkets news